Effect of cyclosporin, previous third-party transfusion, and pregnancy on antibody development after donor-specific transfusion before renal transplantation

A M MacLeod, A N Hillis, A Mather, J M Bone, G R Catto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Non-cytotoxic and cytotoxic antibodies were sought after donor-specific transfusion (DST) in 12 potential renal transplant recipients given concomitant cyclosporin therapy and 13 given DST alone. Non-cytotoxic antibodies, which have been shown to develop after third-party transfusion and to be associated with successful transplantation, developed after DST whether or not cyclosporin was given. Donor and panel reactive lymphocytotoxic antibodies developed relatively infrequently after DST with or without cyclosporin. Donor-specific sensitisation occurred only in patients who were multiparous or had over 10 third-party transfusions. Non-cytotoxic Fc-receptor-blocking antibodies may play a part in the improved survival of one-haplotype-mismatched transplants pretreated with DST.
Original languageEnglish
Pages (from-to)416-418
Number of pages3
JournalThe Lancet
Volume1
Issue number8530
DOIs
Publication statusPublished - 21 Feb 1987

Fingerprint

Kidney Transplantation
Cyclosporine
Tissue Donors
Pregnancy
Antibodies
Blocking Antibodies
Antilymphocyte Serum
Fc Receptors
Haplotypes
Transplantation
Transplants
Kidney

Keywords

  • antibodies
  • antibody formation
  • blood donors
  • blood transfusion
  • cyclosporins
  • evaluation studies as topic
  • female
  • humans
  • immunization
  • kidney transplantation
  • parity
  • pregnancy
  • premedication
  • prospective studies
  • receptors, Fc
  • T-Lymphocytes, cytotoxic
  • time factors
  • tissue donors

Cite this

Effect of cyclosporin, previous third-party transfusion, and pregnancy on antibody development after donor-specific transfusion before renal transplantation. / MacLeod, A M; Hillis, A N; Mather, A; Bone, J M; Catto, G R.

In: The Lancet, Vol. 1, No. 8530, 21.02.1987, p. 416-418.

Research output: Contribution to journalArticle

@article{a409b719100142a69edfdfca68a9a667,
title = "Effect of cyclosporin, previous third-party transfusion, and pregnancy on antibody development after donor-specific transfusion before renal transplantation",
abstract = "Non-cytotoxic and cytotoxic antibodies were sought after donor-specific transfusion (DST) in 12 potential renal transplant recipients given concomitant cyclosporin therapy and 13 given DST alone. Non-cytotoxic antibodies, which have been shown to develop after third-party transfusion and to be associated with successful transplantation, developed after DST whether or not cyclosporin was given. Donor and panel reactive lymphocytotoxic antibodies developed relatively infrequently after DST with or without cyclosporin. Donor-specific sensitisation occurred only in patients who were multiparous or had over 10 third-party transfusions. Non-cytotoxic Fc-receptor-blocking antibodies may play a part in the improved survival of one-haplotype-mismatched transplants pretreated with DST.",
keywords = "antibodies, antibody formation, blood donors, blood transfusion, cyclosporins, evaluation studies as topic, female, humans, immunization, kidney transplantation, parity, pregnancy, premedication, prospective studies, receptors, Fc, T-Lymphocytes, cytotoxic, time factors, tissue donors",
author = "MacLeod, {A M} and Hillis, {A N} and A Mather and Bone, {J M} and Catto, {G R}",
year = "1987",
month = "2",
day = "21",
doi = "10.1016/S0140-6736(87)90121-8",
language = "English",
volume = "1",
pages = "416--418",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "8530",

}

TY - JOUR

T1 - Effect of cyclosporin, previous third-party transfusion, and pregnancy on antibody development after donor-specific transfusion before renal transplantation

AU - MacLeod, A M

AU - Hillis, A N

AU - Mather, A

AU - Bone, J M

AU - Catto, G R

PY - 1987/2/21

Y1 - 1987/2/21

N2 - Non-cytotoxic and cytotoxic antibodies were sought after donor-specific transfusion (DST) in 12 potential renal transplant recipients given concomitant cyclosporin therapy and 13 given DST alone. Non-cytotoxic antibodies, which have been shown to develop after third-party transfusion and to be associated with successful transplantation, developed after DST whether or not cyclosporin was given. Donor and panel reactive lymphocytotoxic antibodies developed relatively infrequently after DST with or without cyclosporin. Donor-specific sensitisation occurred only in patients who were multiparous or had over 10 third-party transfusions. Non-cytotoxic Fc-receptor-blocking antibodies may play a part in the improved survival of one-haplotype-mismatched transplants pretreated with DST.

AB - Non-cytotoxic and cytotoxic antibodies were sought after donor-specific transfusion (DST) in 12 potential renal transplant recipients given concomitant cyclosporin therapy and 13 given DST alone. Non-cytotoxic antibodies, which have been shown to develop after third-party transfusion and to be associated with successful transplantation, developed after DST whether or not cyclosporin was given. Donor and panel reactive lymphocytotoxic antibodies developed relatively infrequently after DST with or without cyclosporin. Donor-specific sensitisation occurred only in patients who were multiparous or had over 10 third-party transfusions. Non-cytotoxic Fc-receptor-blocking antibodies may play a part in the improved survival of one-haplotype-mismatched transplants pretreated with DST.

KW - antibodies

KW - antibody formation

KW - blood donors

KW - blood transfusion

KW - cyclosporins

KW - evaluation studies as topic

KW - female

KW - humans

KW - immunization

KW - kidney transplantation

KW - parity

KW - pregnancy

KW - premedication

KW - prospective studies

KW - receptors, Fc

KW - T-Lymphocytes, cytotoxic

KW - time factors

KW - tissue donors

U2 - 10.1016/S0140-6736(87)90121-8

DO - 10.1016/S0140-6736(87)90121-8

M3 - Article

VL - 1

SP - 416

EP - 418

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8530

ER -